1.64

0.38% -0.00

Taysha Gene Therapies Inc (TSHA)

Overview News Price History Option Chain Financials Discussions Forecast

Taysha Gene Therapies Inc stock is traded at $1.64, with a volume of 237.72K. It is down -0.38% in the last 24 hours and up +6.78% over the past month. Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Previous Close:

$1.64

Open:

$1.64

24h Volume:

237.72K

Relative Volume:

0.08

Market Cap:

$336.11M

Revenue:

$12.87M

Net Income/Loss:

$-114.34M

P/E Ratio:

-1.8968

EPS:

-0.8646

Net Cash Flow:

$-79.23M

1W Performance:

+0.23%

1M Performance:

+6.78%

6M Performance:

-27.71%

1Y Performance:

-35.17%

1-Day Range:

$1.635

$1.71

1-Week Range:

$1.58

$1.74

52-Week Range:

$1.19

$4.32

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name

Taysha Gene Therapies Inc

Sector

Healthcare (1173)

Industry

Biotechnology (677)

Phone

(214) 612-0000

Address

3000 PEGASUS PARK DRIVE, DALLAS

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TSHA's Discussions on Twitter

Compare TSHA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TSHA Taysha Gene Therapies Inc	1.635	336.11M	12.87M	-114.34M	-79.23M	-0.8646
VRTX Vertex Pharmaceuticals Inc	481.05	123.34B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	697.47	76.09B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	648.71	39.34B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	252.04	32.49B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	117.17	28.26B	3.30B	-501.07M	1.03B	-2.1146

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Apr-09-24	Initiated	Piper Sandler	Overweight
Feb-01-23	Downgrade	Jefferies	Buy → Hold
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-22	Downgrade	Goldman	Buy → Neutral
Mar-09-22	Initiated	Robert W. Baird	Outperform
Mar-01-22	Initiated	Wells Fargo	Overweight
Feb-18-22	Initiated	SMBC Nikko	Outperform
Dec-16-21	Initiated	Guggenheim	Buy
Jul-16-21	Initiated	Needham	Buy
Jun-24-21	Initiated	Truist	Buy
Jun-15-21	Initiated	BTIG Research	Buy
Jun-09-21	Initiated	Wedbush	Outperform
Jun-08-21	Initiated	JMP Securities	Mkt Outperform
May-19-21	Initiated	Cantor Fitzgerald	Overweight
May-11-21	Resumed	Jefferies	Buy
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Chardan Capital Markets	Buy
Oct-19-20	Initiated	Goldman	Buy
Oct-19-20	Initiated	Jefferies	Buy
Oct-19-20	Initiated	Morgan Stanley	Overweight

View All

Taysha Gene Therapies Inc Stock (TSHA) Latest News

02:07 AM

Taysha Gene Therapies (TSHA) Projected to Post Earnings on Wednesday - Defense World

02:07 AM

Feb 20, 2025

Taysha Gene Therapies to Release Full-Year 2024 Financial - GlobeNewswire

Feb 20, 2025

Feb 19, 2025

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - The Manila Times

Feb 19, 2025

Gene Therapy Pioneer Taysha Readies Crucial 2024 Financial DisclosureHere's When - StockTitan

Feb 19, 2025

Feb 17, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Brokerages - Defense World

Feb 17, 2025

Feb 15, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by SG Americas Securities LLC - Defense World

Feb 15, 2025

Feb 14, 2025

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 1.3%Time to Buy? - MarketBeat

Feb 14, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Feb 14, 2025

Feb 12, 2025

Critical Analysis: Creative Medical Technology (NASDAQ:CELZ) vs. Taysha Gene Therapies (NASDAQ:TSHA) - Defense World

Feb 12, 2025

Feb 07, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 07, 2025